Lurasidone vs Paliperidone palmitate (Invega Sustenna)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Lurasidone

Marketed by Sumitomo Pharma and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00549718 · Phase 3 · completed

The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).

Reported efficacy

Mean change in Total PANSS Score From Baseline at Week 6: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. (met)

Result source: NCT03465787

Paliperidone palmitate (Invega Sustenna)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Partial signal

NCT00101634 · Phase 3 · completed

The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.

Next expected readout: December 2026 · NCT07493551 (registry estimate)

Reported efficacy

Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)

Result source: NCT02431702

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLurasidonePaliperidone palmitate (Invega Sustenna)
PANSS total, change-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
CGI-S, change-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351
PANSS response—Not posted · NCT01143090—Not posted · NCT00101634
PSP, change—Not posted · NCT011430908.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351
Relapse (% of patients)20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698—Not posted · NCT00101634

PANSS total, change

Lurasidone
-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
Paliperidone palmitate (Invega Sustenna)
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769

CGI-S, change

Lurasidone
-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
Paliperidone palmitate (Invega Sustenna)
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351

PANSS response

Lurasidone
—Not posted · NCT01143090
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634

PSP, change

Lurasidone
—Not posted · NCT01143090
Paliperidone palmitate (Invega Sustenna)
8.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351

Relapse (% of patients)

Lurasidone
20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Lurasidone: 7 of 7 rows · Paliperidone palmitate (Invega Sustenna): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLurasidone
Rows use multiple source trials
Paliperidone palmitate (Invega Sustenna)
Rows use multiple source trials
EQ-5D Index
absolute change · score
0.041 vs -0.042 placebo score @ 6wk20 mga,b,c,d
NCT01821378 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.095 vs -0.042 placebo score @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
0.1 vs 0.12 Oral Antipsychotics score @ 104wkb,c,d
NCT01081769 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-16.6 score @ 6wk160 mga,e,b,c,f
NCT01821378 · Phase 3 · registry result, not featured evidence
show 1 more dose
-8.9 score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
57.4 score @ 13.14wk150 mga,e,b,c,f
NCT01606254 · Phase 2 · registry result, not featured evidence
show 3 more doses
60.2 score @ 13.14wk100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
60.6 score @ 13.14wk150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
56.4 score @ 13.14wk50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Time to First Relapse
time to event · months
NA vs 6.31 placebo monthsb,c,g
NCT01435928 · Phase 3 · registry result, not featured evidence
20.24 vs 19.81 Oral Antipsychotics months*b,c,g
NCT01081769 · Phase 3 · registry result, not featured evidence · converted to months from 616 days as posted
Dropout rate
32.8%40mgh
NCT00549718 · Phase 3 · monotherapy
show 42 more results
31.5%120mg
NCT00549718 · Phase 3 · monotherapy
30.1%80mg
NCT00549718 · Phase 3 · monotherapy
35.8%40 mg
NCT00615433 · Phase 3 · monotherapy
44.5%120 mg
NCT00615433 · Phase 3 · monotherapy
0%Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
33.3%
NCT01569659 · Phase 4 · registry result, not featured evidence
11.1%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
9.4%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
14.4%
NCT02002832 · Phase 3 · registry result, not featured evidence
44%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
29.3%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
25.2%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
26.7%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
75.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
18.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
41.8%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
55.6%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
21.6%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
17%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
18.3%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
65.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
23.1%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
28.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
33.6%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
36.6%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
22.2%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
88.5%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
42.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
42.4%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
66.7%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
59.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
62%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
59.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
56.3%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
10%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
14.3%
NCT01620060 · Phase 1 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)i
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
59.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
6.4%
NCT01081769 · Phase 3 · registry result, not featured evidence
40.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
24.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
44.8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
46.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
48.1%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
14.3%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.8%40mgh
NCT00549718 · Phase 3 · monotherapy
show 42 more results
5.6%120mg
NCT00549718 · Phase 3 · monotherapy
6.5%80mg
NCT00549718 · Phase 3 · monotherapy
—40 mg
NCT00615433 · Phase 3 · monotherapy
—120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
—
NCT01569659 · Phase 4 · registry result, not featured evidence
4.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
2.8%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
—
NCT02002832 · Phase 3 · registry result, not featured evidence
—40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
6.2%
NCT01485640 · Phase 3 · registry result, not featured evidence
—
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
6.3%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.9%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.8%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
6.8%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
6.1%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
—
NCT00641745 · Phase 3 · registry result, not featured evidence
—160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
8.6%
NCT01620060 · Phase 1 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)i
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
2.2%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—
NCT01081769 · Phase 3 · registry result, not featured evidence
17%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
3.1%
NCT00589914 · Phase 3 · registry result, not featured evidence
8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.3%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Serious AEs
1.6%40mgh
NCT00549718 · Phase 3 · monotherapy
show 42 more results
4.8%120mg
NCT00549718 · Phase 3 · monotherapy
2.5%80mg
NCT00549718 · Phase 3 · monotherapy
1.7%40 mg
NCT00615433 · Phase 3 · monotherapy
5.1%120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
7.1%Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
3%
NCT01569659 · Phase 4 · registry result, not featured evidence
3.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
0.5%
NCT02002832 · Phase 3 · registry result, not featured evidence
11%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
2.7%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
3%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
3%80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
4.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
6.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
4.2%
NCT01435928 · Phase 3 · registry result, not featured evidence
7.6%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
12.5%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
4.2%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
2.3%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
0%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
11%
NCT00641745 · Phase 3 · registry result, not featured evidence
3.3%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
0.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
6.3%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
5.3%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
0%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
20.3%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
2.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
18.2%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.1%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
5.6%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
13.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
4.2%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
1.9%
NCT01620060 · Phase 1 · registry result, not featured evidence
12.8%Part 2-Paliperidone Palmitate (PP)i
NCT02431702 · Phase 3
show 16 more results
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
18.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
5%Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
11.2%
NCT01081769 · Phase 3 · registry result, not featured evidence
6.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
3.9%Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
6.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
—150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
14.3%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40mgh
headache 18.5% (placebo 15.7%)
akathisia 11.3% (placebo 51.2%)
nausea 11.3% (placebo 7.1%)
NCT00549718 · Phase 3 · monotherapy
show 41 more results
120mg
akathisia 24.2% (placebo 51.2%)
headache 16.9% (placebo 15.7%)
somnolence 14.5% (placebo 5.5%)
NCT00549718 · Phase 3 · monotherapy
80mg
akathisia 17.4% (placebo 51.2%)
headache 13.2% (placebo 15.7%)
sedation 10.7% (placebo 4.7%)
NCT00549718 · Phase 3 · monotherapy
40 mg
headache 21.8% (placebo 21.6%)
insomnia 12.6% (placebo 11.2%)
akathisia 11.8% (placebo 0.9%)
NCT00615433 · Phase 3 · monotherapy
120 mg
akathisia 22.9% (placebo 0.9%)
headache 17.8% (placebo 21.6%)
somnolence 15.3% (placebo 4.3%)
NCT00615433 · Phase 3 · monotherapy
insomnia 21.4%
sedation 21.4%
stiffness in jaw 14.3%
NCT02199743 · Phase 4 · registry result, not featured evidence
nausea 27.3%
headache 15.2%
insomnia 12.1%
NCT01569659 · Phase 4 · registry result, not featured evidence
40 mg
nausea 12.7% (placebo 2.7%)
anxiety 10% (placebo 8%)
akathisia 9.1% (placebo 1.8%)
NCT01911429 · Phase 3 · registry result, not featured evidence
80 mg
nausea 14.4% (placebo 2.7%)
somnolence 11.5% (placebo 5.4%)
headache 10.6% (placebo 12.5%)
NCT01911429 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 17%
consitpation 12.9%
insomnia 9.8%
NCT02002832 · Phase 3 · registry result, not featured evidence
40-mg or 80-mg
insomnia 11.3%
akathisia 11%
nasopharyngitis 10.6%
NCT01614912 · Phase 3 · registry result, not featured evidence
40 mg
headache 9.3% (placebo 7.9%)
constipation 8.7% (placebo 7.9%)
akathisia 7.3% (placebo 3.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 10.4% (placebo 3.3%)
nausea 7.8% (placebo 4.6%)
anxiety 7.1% (placebo 5.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
20 mg
insomnia 15.8% (placebo 21.4%)
headache 9.9% (placebo 7.1%)
anxiety 7.9% (placebo 6.3%)
NCT01821378 · Phase 3 · registry result, not featured evidence
80-160 mg
akathisia 10.6% (placebo 1.8%)
insomnia 10.6% (placebo 21.4%)
nausea 8.6% (placebo 3.6%)
NCT01821378 · Phase 3 · registry result, not featured evidence
headache 5.6%
diarrhoea 3.7%
influenza 3.7%
NCT01485640 · Phase 3 · registry result, not featured evidence
akathisia 5.2%
schizophrenia 4.2%
nasopharyngitis 2.6%
NCT01566162 · Phase 3 · registry result, not featured evidence
schizophrenia 6.9% (placebo 7.8%)
insomnia 6.3% (placebo 7.1%)
anxiety 4.2% (placebo 2.8%)
NCT01435928 · Phase 3 · registry result, not featured evidence
160 mg
headache 13.9%
akathisia 10.1%
insomnia 8.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 15.3%
headache 6.9%
insomnia 6.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
40/40
nausea 13.9%
headache 9.7%
somnolence 9.7%
NCT01143077 · Phase 3 · registry result, not featured evidence
40/80
insomnia 18.4%
akathisia 14.9%
headache 11.5%
NCT01143077 · Phase 3 · registry result, not featured evidence
80/80
nausea 18.5%
insomnia 14.8%
akathisia 13.6%
NCT01143077 · Phase 3 · registry result, not featured evidence
nausea 16.7%
insomnia 15.8%
sedation 14.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
160 mg
headache 9.9% (placebo 10.7%)
akathisia 7.4% (placebo 0.8%)
vomiting 7.4% (placebo 5%)
NCT00790192 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 11.2% (placebo 9.1%)
headache 9.6% (placebo 10.7%)
akathisia 8% (placebo 0.8%)
NCT00790192 · Phase 3 · registry result, not featured evidence
40 mg
insomnia 14.2% (placebo 14.4%)
schizophrenia 11.8% (placebo 18.9%)
nasopharyngitis 10.2% (placebo 9.8%)
NCT00711269 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 19.1% (placebo 14.4%)
schizophrenia 19.1% (placebo 18.9%)
akathisia 11.5% (placebo 4.5%)
NCT00711269 · Phase 3 · registry result, not featured evidence
flexible dose
nausea 33.3%
NCT01731119 · Phase 2 · registry result, not featured evidence
80 mg
bronchitis 6.8%
nausea 6.8%
sedation 6.8%
NCT00088621 · Phase 2 · registry result, not featured evidence
80 mg
nausea 16.7% (placebo 3.3%)
constipation 11.1% (placebo 5.6%)
headache 11.1% (placebo 10%)
NCT00088634 · Phase 2 · registry result, not featured evidence
40 mg
dizziness 18.2%
headache 15.2%
nasopharyngitis 12.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
80 mg
headache 15.2%
depression 12.1%
oropharyngeal pain 9.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
20 mg
headache 15.6%
insomnia 9.4%
nasopharyngitis 9.4%
NCT00044005 · Phase 2 · registry result, not featured evidence
headache 21.1% (placebo 33.3%)
dyspepsia 11.3% (placebo 9.7%)
nausea 11.3% (placebo 11.1%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 16.4% (placebo 8.3%)
agitation 13.4% (placebo 4.2%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 21.1% (placebo 8.3%)
akathisia 18.3% (placebo 9.7%)
NCT00044044 · Phase 2 · registry result, not featured evidence
40 mg
somnolence 75% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
irritability 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
80 mg
somnolence 100% (placebo 33.3%)
blood prolactin increased 83.3% (placebo 22.2%)
dizziness 25% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
20 mg
somnolence 62.5% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
feeling hot 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
40mg
somnolence 100% (placebo 0%)
blood prolactin increased 60% (placebo 25%)
restlessness 60% (placebo 0%)
NCT02174523 · Phase 1 · registry result, not featured evidence
somnelence 41.9%
sedation 18.1%
nausea 17.1%
NCT01620060 · Phase 1 · registry result, not featured evidence
i
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3
show 16 more results
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3
injection site pain 18.6%
insomnia 18.6%
weight increased 13.3%
NCT01157351 · Phase 4 · registry result, not featured evidence
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
weight increased 15.4%
insomnia 11.2%
headache 10.6%
NCT01081769 · Phase 3 · registry result, not featured evidence
insomnia 17% (placebo 15.2%)
injection site pain 13.2% (placebo 6.7%)
nasopharyngitis 12.6% (placebo 6.1%)
NCT01299389 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.4% (placebo 6.1%)
constipation 5.2% (placebo 5.5%)
insomnia 3.9% (placebo 15.2%)
NCT01299389 · Phase 3 · registry result, not featured evidence
insomnia 9.4%
headache 7.1%
somnolence 5.6%
NCT00589914 · Phase 3 · registry result, not featured evidence
150 mg eq.
injection site pain 8% (placebo 3.7%)
headache 6.1% (placebo 7.3%)
akathisia 5.5% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
100 mg eq.
headache 6.7% (placebo 7.3%)
injection site pain 6.1% (placebo 3.7%)
akathisia 4.8% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
25 mg eq.
headache 10.6% (placebo 7.3%)
injection site pain 8.8% (placebo 3.7%)
akathisia 1.3% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
150 mg
blood prolactin increased 92.9%
insomnia 28.6%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
100 mg
blood prolactin increased 64.3%
psychiatric symptom 42.9%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
150/ 50 mg
blood prolactin increased 71.4%
nasopharyngitis 28.6%
alanine aminotransferase increased 21.4%
NCT01606254 · Phase 2 · registry result, not featured evidence
50 mg
blood prolactin increased 78.6%
nasopharyngitis 35.7%
psychiatric symptom 35.7%
NCT01606254 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 104 weeks versus 6 weeks.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 13.14 weeks versus 6 weeks.
  7. gThe assessment timepoint is not available for both results.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lurasidone

BACS Composite -2.002433521 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT02199743 · Phase 4 · registry result, not featured evidence
PANSS Positive Subscale 24.2 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01569659 · Phase 4 · registry result, not featured evidence
PANSS Positive -6.3 vs -3.1 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 3 more results
-2 vs -0.6 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-6.3 vs -3.1 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.6 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS 20 63.9% (n=108) vs 61.6% (n=112) placebo @ 6wk40 mg
responder rate · % of participants
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 69 number of participants as posted
show 3 more results
44.3% (n=106) vs 61.6% (n=112) placebo @ 6wk*80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 47 number of participants as posted
44% (n=101) vs 73% (n=112) placebo @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
53% (n=198) vs 73% (n=112) placebo @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
PQLES Total 5.6 vs 0.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
6.1 vs 0.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGAS 11.3 vs 7.5 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
11.9 vs 7.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -8.1 vs -5.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 5 more results
-8.8 vs -6.3 placebo score @ 6wk40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-2.4 vs -1 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-8.1 vs -5.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.3 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-1.2 vs -1 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.6 vs -2.4 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.7 vs -2.4 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGI-I 2 vs 1.9 Risperidone score @ 6wk
absolute value · score
NCT02002832 · Phase 3 · registry result, not featured evidence
PANSS Total -28.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-8.4 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
CGI-S -1.46 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-0.48 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale -8.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

Paliperidone palmitate (Invega Sustenna)

Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3
show 2 more results
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3
13.67 vs 7.43 Oral Antipsychotics months*
NCT01157351 · Phase 4 · registry result, not featured evidence · converted to months from 416 days as posted
MCCB Composite 1.6 vs 3.2 Oral Antipsychotics T-score @ 78.2wk
absolute change · T-score
NCT02431702 · Phase 3
show 3 more results
-0.7 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
-0.2 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
2 vs 2.8 Oral Antipsychotics T-score @ 39.1wk
NCT02431702 · Phase 3
PSP 8.3 vs 1.7 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 16 more results
6.1 vs 1.7 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3
5.75 vs 5.36 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
1 vs 1.1 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
4.9 vs 4.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
7.6 vs 7.7 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
9.9 vs 10.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
11.4 vs 11.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.7 vs 12.3 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.9 vs 12.9 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14 vs 13.3 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14.7 vs 14 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
15.2 vs 14.6 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
8.5 vs 8.8 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
MCCB Working Memory -0.2 vs -0.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-1.7 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Verbal Learning 1.3 vs 1 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.3 vs 0.8 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Speed of Processing 1.8 vs 3.5 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.5 vs 4.9 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Attention/Vigilance 3.2 vs 0.7 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.4 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Visual Learning 1.3 vs 1.4 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.2 vs -0.2 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Reasoning Problem Solving 0.2 vs 2.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
3.4 vs 4.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Social Cognition 0.3 vs 1.6 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-0.2 vs 1.4 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
Time to First Psychiatric Hospitalization or Arrest/Incarceration NA vs 9 Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence
Time to First Psychiatric Hospitalization NA vs NA Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lurasidone's landscape · Paliperidone palmitate (Invega Sustenna)'s landscape